Antisoma To Amend ACCEDE Phase III Study Of AS1413

Links shared publicly online about this topic.

  • 1,691
    total visits

Antisoma To Amend ACCEDE Phase III Study Of AS1413

medicalnewstoday.com —

Antisoma announces that, following discussions with fda and trial investigators, it plans to amend the primary endpoint in the accede study of as1413. the accede study is an ongoing randomised, co

View full resource at medicalnewstoday.com

Tags: FDA

  • Share

Most Recently Shared on October 9, 2009 at 1:58 am By:

mnt_clinical MNT Clinical Trials

Antisoma To Amend ACCEDE Phase III Study Of AS1413: Antisoma announces that, following discussions with FDA and.. http://bit.ly/242QB8

3 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Cancer News MNT Cancer News

Advertisement